As of 2025-06-22, the Intrinsic Value of Arcutis Biotherapeutics Inc (ARQT) is 7.76 USD. This Arcutis valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 13.82 USD, the upside of Arcutis Biotherapeutics Inc is -43.90%.
The range of the Intrinsic Value is 4.84 - 10.41 USD
Based on its market price of 13.82 USD and our intrinsic valuation, Arcutis Biotherapeutics Inc (ARQT) is overvalued by 43.90%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (117.54) - (26.60) | (40.94) | -396.2% |
| DCF (Growth 10y) | (20.39) - (70.50) | (28.47) | -306.0% |
| DCF (EBITDA 5y) | 4.84 - 10.41 | 7.76 | -43.9% |
| DCF (EBITDA 10y) | 1.82 - 10.50 | 5.96 | -56.8% |
| Fair Value | -5.44 - -5.44 | -5.44 | -139.37% |
| P/E | (13.82) - (28.51) | (22.64) | -263.8% |
| EV/EBITDA | (15.29) - (11.41) | (14.78) | -206.9% |
| EPV | (14.72) - (23.10) | (18.91) | -236.8% |
| DDM - Stable | (10.39) - (70.80) | (40.59) | -393.7% |
| DDM - Multi | (8.84) - (49.06) | (15.21) | -210.1% |
| Market Cap (mil) | 1,647.34 |
| Beta | 0.79 |
| Outstanding shares (mil) | 119.20 |
| Enterprise Value (mil) | 1,701.86 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.36% |
| Cost of Debt | 7.00% |
| WACC | 8.16% |